Designing Microscopy Experiments Related To Infectious Diseases And Antivirals

Designing microscopy experiments related to infectious diseases and antivirals can be challenging, but there’s never been a more vital time than right now to design adequate microscopy experiments. The novel coronavirus (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and spread across the globe becoming the pandemic that the world is reeling with today. Currently, COVID-19  has no targeted therapies approved by the FDA, so the best coronavirus prevention happens through social distancing and good hygiene practices. However, companies are rapidly testing candidate molecules and vaccines as fast as they can. Initial tests suggest there may be some drugs that could be repurposed for COVID-19 treatment. Repurposed drugs have already shown their safety, so clinical trials need to be conducted for effectiveness only. 

SARS-CoV2 belongs to a family of viruses that we’ve encountered before, so there is hope that we can apply the knowledge we have about SARS and MERS for treatment. Looking towards the future, since 75% of emerging infections have come from animals (zoonosis) we will continue to see new pathogens in our lifetimes. What does the research & development pipeline look like for combating these new infectious diseases?  

In 2013, I worked for a company called Evrys that works on host-directed antivirals. Drugs like these are special because the therapeutic target is our cells instead of the virus directly. There are different pathways towards a successful drug, but this outline should be applicable to many research and development (R&D) workflows. Here, we will go over the steps that R&D takes to develop new treatments and how microscopy assists with the research.

Taken from Hughes et al. 2010

1. Determine a druggable target.

Viruses can be grouped into a major class even if they are new.  All coronaviruses (including SARS-CoV & MERS-CoV) are enveloped positive-sense RNA viruses that have club-like spikes on their surface and similar life cycle steps, allowing for prior knowledge of similar viruses to be used. If we encounter a new virus, sequencing the genome and obtaining electron microscopy images is the best place to start to determine what type of virus we are dealing with. Common antiviral targets interfere with receptor binding, membrane fusion/entry, replication, protein translation, and viral release. While writing this, Clinicaltrails.gov listed 112 active clinical trials for COVID-19 treatment. Current targets include RNA-dependent RNA polymerase (remdesivir, favipiravir) and viral entry (Baricitinib, ACE inhibitors). Knowing the target can help narrow down the compounds used in the primary screen, but it is not necessary due to the simple readout of “virus” or “no virus.”

2. Primary Screens

Primary screens are when scientists test compounds (numbering from 1K to 10K) for antiviral activity. The “effective concentration” is the concentration of product at which virus replication is inhibited by 50%, e.g. EC50 for cell-based assays and IC50 for biochemical or subcellular assays.

The most common microscopy technique used in this stage of drug development is high throughput screening (HTS). There are a variety of microscopes that are capable of HTS, but they all share similar features.  These microscopes accept 96-well to 1536-well plates and automatically image all the wells for the users. 

Ideally, specific antibodies have been produced at this point to allow for fluorescence microscopy.    

This entails using widefield or confocal microscopes to observe a decrease in viral load, as well as cytopathic effects (structural cell changes). Cytopathic effects can often be seen using phase contrast or DIC microscopy.  For more information on determining the health of your cells, check out our 6 Microscopy Assays To Determine Cell Health and Improve Your Experimental Results blog.

3. Secondary Screens

Once a potential drug has been identified, it is important to ensure that there are not any unintended side effects on healthy cells. The goal is to stop viral replication without killing the uninfected cells. This work again uses a HCS microscope. It tests a series of increasing concentrations of the possible drugs to determine the concentration at which the compound kills 50% of the cells (known as CC50 value). The concentration for which the compound kills 50% of the cell in culture is divided by the concentration needed to kill 50% of the virus, giving us a therapeutic index. The therapeutic index is important because it provides the difference in concentration between when it is helpful and when it could be toxic to the patient. Many over the counter drugs such as Claritin (loratadine) have a high therapeutic index and thus it’s difficult for a patient to overdose. The drugs that have the best therapeutic index will undergo further optimization with chemists making many small changes. And you guessed it, more cellular assays on HCS microscope to ensure safety.

4. Antiviral Activity in Vivo 

A lot of good information can come from in vitro studies, but they can’t replicate the effects observed in a whole organism. This is where in vivo studies become useful. In vivo studies generally rely on developing an animal model of the infection and treating it with possible drugs. Work on coronavirus is currently being performed using a specialized mouse that has the human ACE2 receptor.  

Animal studies study the effect of the drug on a whole-body level. The main goal is to determine important information for regulatory agencies such as dosage, toxicity, and/or carcinogenicity. For a more complete list of parameters check here. During the course of the in vivo study, researchers measure parameters such as weight and temperature regularly.  After the animal dies, researchers use brightfield microscopy and histological staining of tissues and blood to determine any toxic or carcinogenic damage that has occurred due to treatment.  

The most basic of the assays is staining tissue sections from different organs with hematoxylin and eosin (H&E). Animal studies for coronavirus would obviously examine the lungs, but it is also important to examine any histopathological changes in the gastrointestinal tract, liver, kidneys, heart, thyroid, and brain. Drug side effects occur when there are off-target effects in the cells. Although anyone can perform the histology sample preparation and imaging, someone with proper pathology training should analyze the samples. Imaging can be done using any brightfield microscope, but drug development companies have moved to use slide scanners. Slide scanners are digital microscopes that image the entire slide (or specified region) and can image 100s of slides each day. Not only do slide scanners allow high throughput imaging, but they can achieve incredible reproducibility.  

Other microscope assays that are important in the in vivo stage are blood smears and apoptosis assays. Blood smears are paired with histological dyes to examine changes in red blood cells, white blood cells, and platelets. Changes in these blood components can be an indicator of more serious systemic changes.  Finally, apoptosis assays are important to determine any cellular death caused by the antiviral.  There are a variety of different ways to measure apoptosis, but in tissue sections, TUNEL assays are the preferred method due to the simplicity and the ability to perform the assay in a high throughput manner. 

Microscopes are necessary at several stages of the research and development of antivirals. Time is very valuable, especially with the current pandemic, so learning to use high throughput machines is key to being successful. Although many of the features are automated, it is important to know enough about the microscope and the biology to ensure biologically relevant data are obtained. Just like in normal microscopy, don’t forget the proper controls! You don’t want thousands of pictures that are of no use to you or even worse, follow an incorrect lead during development.

To learn more about important control measures for your flow cytometry lab, and to get access to all of our advanced materials including 20 training videos, presentations, workbooks, and private group membership, get on the Flow Cytometry Mastery Class wait list.

Join Expert Cytometry's Mastery Class
Heather Brown-Harding
Heather Brown-Harding

Heather Brown-Harding, PhD, is currently the assistant director of Wake Forest Microscopy and graduate teaching faculty.She also maintains a small research group that works on imaging of host-pathogen interactions. Heather is passionate about making science accessible to everyone.High-quality research shouldn’t be exclusive to elite institutions or made incomprehensible by unnecessary jargon. She created the modules for Excite Microscopy with this mission.

In her free time, she enjoys playing with her cat & dog, trying out new craft ciders and painting.You can find her on twitter (@microscopyEd) a few times of day discussing new imaging techniques with peers.

Similar Articles

The Power Of Spectral Viewers And Their Use In Full Spectrum Flow Cytometry

The Power Of Spectral Viewers And Their Use In Full Spectrum Flow Cytometry

By: Tim Bushnell, PhD

What photon from yonder fluorochrome breaks?  It is … umm… hmmm. Let me see. Excitation off a 561 nm laser, with an emission maximum of 692 nm. I’m sure if Shakespeare was a flow cytometrist, he might have written that very scene. But the play is lost in time. However, since the protagonist had difficulty determining what fluorochrome was emitting photons, let’s consider how this could be figured out. In my opinion, one of the handiest flow cytometry tools is the spectral viewer. This tool helps visualize the excitation and emission profile of different fluorochromes, as well as allowing you…

Fickle Markers: Solutions For Antibody Binding Specificity Challenges

Fickle Markers: Solutions For Antibody Binding Specificity Challenges

By: Tim Bushnell, PhD

Reproducibility has been an ongoing, and important, concept in the sciences for years.  In the area of biomedical research, the alarm was sounded by several papers published in the early 2010’s.  Authors like Begley and Ellis, Prinz and coworkers, and Vasilevsky and colleagues, among others reported an alarming trend in the reproducibility of pre-clinical data.  These reports indicated between 50% to almost 90% of published pre-clinical data were not reproducible.  This was further highlighted in the article by Freedman and coworkers, who tried to identify and quantify the different sources of error that could be causing this crisis.  Figure 1,…

5 Common Flow Cytometry Questions, Answered

5 Common Flow Cytometry Questions, Answered

By: Tim Bushnell, PhD

I want to thank all of you who send us your questions about flow cytometry, so I thought I would dip into the old email bag and answer a few of the common ones here.  If your question isn’t answered this time, look for it to be answered in a future blog post.  Of course, if you want us to cover a specific topic, drop us a line.  1. How Fast Can I Go? This is  a common question. The allure of the ‘hi’ button is hard to resist.  The faster you go, the sooner you are finished with data…

Combining Flow Cytometry With Plant Science, Microorganisms, And The Environment

Combining Flow Cytometry With Plant Science, Microorganisms, And The Environment

By: Tim Bushnell, PhD

My first introduction to flow cytometry was talking to a professor who’d brought one on a research cruise to study phytoplankton. It was only later that I was introduced to the marvelous world that’s been my career for over 20 years.   In that time, I’ve had the opportunity to work with researchers in many different areas, exposing me to a wide variety of cell types and more important assays. What continues to amaze me is the number of different parameters we can measure, not just the number of fluorochromes, but the information we can extract from samples – animal, vegetable…

Common Numbers-Based Questions I Get As A Flow Cytometry Core Manager And How To Answer Them

Common Numbers-Based Questions I Get As A Flow Cytometry Core Manager And How To Answer Them

By: Tim Bushnell, PhD

Numbers are all around us.  My personal favorite is ≅1.618 aka ɸ aka ‘the golden ratio’.  It’s found throughout history, where it has influenced architects and artists. We see it in nature, in plants, and it is used in movies to frame shots. It can be approximated by the Fibonacci sequence (another math favorite of mine). However, I have not worked out how to apply this to flow cytometry.  That doesn’t mean numbers aren’t important in flow cytometry. They are central to everything we do, and in this blog, I’m going to flit around numbers-based questions that I have received…

3 Must-Have High-Dimensional Flow Cytometry Controls

3 Must-Have High-Dimensional Flow Cytometry Controls

By: Tim Bushnell, PhD

Developments such as the recent upgrade to the Cytobank analysis platform and the creation of new packages such as Immunocluster are reducing the computational expertise needed to work with high-dimensional flow cytometry datasets. Whether you are a researcher in academia, industry, or government, you may want to take advantage of the reduced barrier to entry to apply high-dimensional flow cytometry in your work. However, you’ll need the right experimental design to access the new transformative insights available through these approaches and avoid wasting the considerable time and money required for performing them. As with all experiments, a good design begins…

The Fluorochrome Less Excited: How To Build A Flow Cytometry Antibody Panel

The Fluorochrome Less Excited: How To Build A Flow Cytometry Antibody Panel

By: Tim Bushnell, PhD

Fluorochrome, antibodies and detectors are important. The journey of a thousand cells starts with a good fluorescent panel. The polychromatic panel is the combination of antibodies and fluorochromes. These will be used during the experiment to answer the biological question of interest. When you only need a few targets, the creation of the panel is relatively straightforward. It’s only when you start to get into more complex panels with multiple fluorochromes that overlap in excitation and emission gets more interesting.  FLUOROCHROMES Both full spectrum and traditional fluorescent flow cytometry rely on measuring the emission of the fluorochromes that are attached…

Flow Cytometry Year in Review: Key Changes To Know

Flow Cytometry Year in Review: Key Changes To Know

By: Meerambika Mishra

Here we are, at the end of an eventful year 2021. But with the promise of a new year 2022 to come. It has been a long year, filled with ups and downs. It is always good to reflect on the past year as we move to the future.  In Memoriam Sir Isaac Newton wrote “If I have seen further, it is by standing upon the shoulders of giants.” In the past year, we have lost some giants of our field including Zbigniew Darzynkiwicz, who contributed much in the areas of cell cycle analysis and apoptosis. Howard Shapiro, known for…

What Star Trek Taught Me About Flow Cytometry

What Star Trek Taught Me About Flow Cytometry

By: Tim Bushnell, PhD

It is no secret that I am a very big fan of the Star Trek franchise. There are many good episodes and lessons explored in the 813+ episodes, 12 movies (and counting). Don’t worry, this blog is not going to review all 813, or even 5 of them. Instead, some of the lessons I have taken away from the show that have applicability to science and flow cytometry.  “Darmok and Jalad at Tanagra.”  (ST:TNG season 5, episode 2) This is probably one of my favorite episodes, which involves Picard and an alien trying to establish a common ground and learn…

Top Technical Training eBooks

Get the Advanced Microscopy eBook

Get the Advanced Microscopy eBook

Heather Brown-Harding, PhD

Learn the best practices and advanced techniques across the diverse fields of microscopy, including instrumentation, experimental setup, image analysis, figure preparation, and more.

Get The Free Modern Flow Cytometry eBook

Get The Free Modern Flow Cytometry eBook

Tim Bushnell, PhD

Learn the best practices of flow cytometry experimentation, data analysis, figure preparation, antibody panel design, instrumentation and more.

Get The Free 4-10 Compensation eBook

Get The Free 4-10 Compensation eBook

Tim Bushnell, PhD

Advanced 4-10 Color Compensation, Learn strategies for designing advanced antibody compensation panels and how to use your compensation matrix to analyze your experimental data.